Tasly and SemBioSys Genetics Inc. Report Progress on their China JV

February 2, 2012 -- Tianjin Tasly Pharma and SemBioSys Genetics of Canada have received business licenses for their Tianjin-based JV, which is based on SemBioSys’ seed-based oilbody and genetic expression technology. Ultimately, the JV expects to use the technology to produce insulin for China and the rest of world. In the near-term, it will develop modernized TCM products and nutraceuticals. After that, the JV will turn its focus toward animal food additives. More details....

Stock Symbols: (SHA: 600535) (TSX: SBS)